Table 5.

Fosfomycin efficacy (DC₅₀) on biofilm-associated MDR UPEC clinical isolates.

ID Isolate	Biofilm-Formation Capacity	Anti-Biofilm Activity DC50 (μg/mL)	ID isolate	Biofilm-Formation Capacity	Anti-Biofilm Activity DC50 (μg/mL)
61	WBP	164.4 ± 1.9	140	MBP	514.7 ± 3.0
117	WBP	175.6 ± 2.2	93	MBP	521.8 ± 6.9
116	WBP	187.1 ± 1.8	7	MBP	522.0 ± 3.1
95	WBP	188.6 ± 4.7	1	WBP	523.1 ± 1.8
43	WBP	189.6 ± 0.7	70	SBP	523.9 ± 5.9
48	WBP	192.0 ± 2.5	127	WBP	526.8 ± 5.7
38	WBP	200.8 ± 1.0	67	MBP	538.4 ± 3.1
27	WBP	206.0 ± 5.1	56	MBP	540.0 ± 4.8
119	WBP	209.0 ± 1.4	21	MBP	551.0 ± 0.9
65	WBP	222.4 ± 4.1	40	MBP	567.7 ± 2.7
52	WBP	243.1 ± 4.6	105	MBP	576.2 ± 2.3
16	WBP	245.1 ± 1.9	63	MBP	589.1 ± 5.7
54	WBP	276.9 ± 1.4	49	MBP	593.2 ± 1.2
34	WBP	278.0 ± 3.0	138	SBP	599.5 ± 4.8
91	WBP	278.0 ± 5.9	87	MBP	599.8 ± 1.4
15	WBP	301.1 ± 3.7	55	MBP	601.2 ± 1.8
122	WBP	307.5 ± 3.3	20	MBP	602.2 ± 2.1
39	WBP	333.2 ± 1.4	112	SBP	620.9 ± 8.5
68	WBP	339.8 ± 1.2	81	MBP	624.6 ± 2.9
53	WBP	340.0 ± 1.6	109	MBP	631.0 ± 2.5
88	WBP	341.8 ± 1.2	74	MBP	645.1 ± 2.1
2	WBP	359.0 ± 2.1	62	MBP	650.6 ± 1.3
33	WBP	364.7 ± 1.0	124	MBP	655.7 ± 4.7
11	WBP	369.6 ± 1.7	71	SBP	663.9 ± 2.6
118	MBP	375.2 ± 5.7	129	MBP	664.0 ± 1.6
92	WBP	378.2 ± 5.2	36	MBP	680.9 ± 2.6
41	MBP	380.8 ± 3.2	60	MBP	698.0 ± 2.3
18	WBP	380.9 ± 2.8	136	SBP	701.5 ± 2.7
5	WBP	400.0 ± 6.1	22	MBP	702.1 ± 1.4
19	WBP	400.1 ± 2.4	29	WBP	710.9 ± 2.6
66	MBP	403.1 ± 1.9	64	SBP	722.0 ± 1.1
10	MBP	419.0 ± 1.2	3	SBP	723.6 ± 2.0
26	WBP	420.7 ± 0.9	80	MBP	751.4 ± 1.8
47	MBP	431.6 ± 1.4	120	MBP	790.8 ± 4.1
28	MBP	444.8 ± 1.3	142	MBP	814.2 ± 5.1
50	MBP	447.0 ± 1.7	128	MBP	880.4 ± 1.7
114	MBP	449.1 ± 1.6	108	SBP	922.6 ± 6.3
139	MBP	461.5 ± 1.2	77	SBP	980.1 ± 1.1
97	MBP	470.9 ± 3.1	126	SBP	989.2 ± 2.6
131	WBP	474.8 ± 1.3	121	SBP	1021.2 ± 1.3
107	MBP	476.3 ± 5.7	76	MBP	1045.0 ± 3.4
101	SBP	500.2 ± 7.8

WBP: weak biofilm producer; MBP: moderate biofilm producer; SBP: strong biofilm producer.